Homira Osman, PhD

VP, Research and Public Policy

Muscular Dystrophy Canada

Dr. Homira Osman joined Muscular Dystrophy Canada (MDC) in 2019. She is trained as an audiologist-scientist and knowledge translation specialist. Homira holds an Honours B.Sc. in Neuroscience and Population Health from the University of Toronto. She earned a clinical doctorate and a PhD in neuroscience from the University of Washington (Seattle), followed by a post-doctoral fellowship at the Hospital for Sick Children in Toronto. At MDC, Homira works closely with persons with lived experience, physicians, allied healthcare professionals, researchers, academic, community and industry partners to engage, learn and share in knowledge generation, synthesis, and mobilization and ensures that evidence turns into action. Homira also oversees the Public Policy portfolio where she engages with officials in the federal and provincial governments to represent the voices and experiences of people living with neuromuscular disorders (NMDs) and ensures meaningful engagement between patient advocacy groups and government, drug regulators, pharmaceutical companies and community partners.

As Vice President of Research and Public Policy, Homira delivers strategic and operational leadership for all elements of MDC’s research portfolio, knowledge translation, clinical relationships and advocacy work. She acts as a key facilitator between members of the Canadian neuromuscular research and clinical community. Homira is also an investigator at the Neuromuscular Disease Network for Canada (NMD4C), serves on the Canadian Institutes of Health Research Community of Practice in Peer Review Steering Committee and is a member of the pan-Canadian Disability Coalition.

All Sessions by Homira Osman, PhD

Printer Friendly See Full Agenda

Agenda: Day 1 Oct 5, 2020

Agenda: Day 2 Oct 6, 2020

2:30 pm

2:30 pm

Panel Discussion: HEALTH ECONOMICS


This session will explore the concept of a societal perspective vs a MOH perspective in economic evaluations. Should certain disease areas be assessed based on a societal perspective? The panel will explore this for rare diseases, Chronic diseases and Cancer.